AnaptysBio, Inc.

Informe acción NasdaqGS:ANAB

Capitalización de mercado: US$1.8b

AnaptysBio Dirección

Dirección controles de criterios 4/4

El CEO de AnaptysBio es Dan Faga , nombrado en Mar 2022, tiene una permanencia de 4.17 años. compensación anual total es $6.13M, compuesta por 11.5% salario y 88.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.71% de las acciones de la empresa, por valor de $30.00M. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 3.9 años, respectivamente.

Información clave

Dan Faga

Chief Executive Officer (CEO)

US$6.1m

Compensación total

Porcentaje del salario del CEO11.51%
Permanencia del CEO4.2yrs
Participación del CEO1.7%
Permanencia media de la dirección2.3yrs
Promedio de permanencia en la Junta Directiva3.9yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Apr 21

AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics

Summary AnaptysBio has spun off its biopharma pipeline into First Tracks Biotherapeutics, shifting to a royalty-focused, virtual business model. I maintain a "Hold" rating on both ANAB and TRAX, given the need for further clinical data and clarity on pipeline advancement and partnerships. ANAB retains royalty streams from JEMPERLI [GlaxoSmithKline] and imsidolimab (Vanda Pharmaceuticals), with JEMPERLI sales growing and a PDUFA date for imsidolimab set for Dec 2026. TRAX's value hinges on upcoming ANB033 data in celiac disease [Q4 2026] and EoE [mid-2027], and potential strategic financing for rosnilimab in RA Q2 2026. Read the full article on Seeking Alpha
Artículo de análisis • Jul 16

AnaptysBio, Inc.'s (NASDAQ:ANAB) Share Price Not Quite Adding Up

With a median price-to-sales (or "P/S") ratio of close to 8.6x in the Biotechs industry in the United States, you could...
Artículo de análisis • Jun 11

Shareholders May Be More Conservative With AnaptysBio, Inc.'s (NASDAQ:ANAB) CEO Compensation For Now

Key Insights AnaptysBio to hold its Annual General Meeting on 17th of June Salary of US$685.4k is part of CEO Dan...
Artículo de análisis • May 08

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

It's been a mediocre week for AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders, with the stock dropping 11% to US$19.68 in...
Artículo de análisis • May 07

Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Artículo de análisis • Apr 03

AnaptysBio, Inc.'s (NASDAQ:ANAB) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Despite an already strong run, AnaptysBio, Inc. ( NASDAQ:ANAB ) shares have been powering on, with a gain of 30% in the...
Seeking Alpha • Mar 06

AnaptysBio: A Shadow Of Its Former Self

Summary ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns. The recent deal for Imsidolimab reflects low confidence in the drug's market potential, despite positive phase 3 results. Rosnilimab showed promising trial results but failed to differentiate significantly from existing treatments, raising doubts about its competitive edge. Financials show a cash runway of 6-7 quarters, but high expenses and limited revenue sources maintain the risk profile. Read the full article on Seeking Alpha
Artículo de análisis • Feb 14

AnaptysBio, Inc. (NASDAQ:ANAB) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders would be excited to see that the share price has had a great month...
Seeking Alpha • Dec 18

AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout

Summary The failure of ANB032 in Phase 2B for atopic dermatitis has shifted focus to rosnilimab, which faces significant competition and uncertain prospects. Rosnilimab's upcoming Phase 2B results for rheumatoid arthritis in February 2025 are crucial, but Eli Lilly's discontinuation of a similar drug raises concerns. If rosnilimab fails to deliver, the company's mid-stage pipeline may not hold much promise any more. Anaptys estimates that it will have about $415 million in the bank at the end of the year. Read the full article on Seeking Alpha
Seeking Alpha • Nov 21

AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching

Summary AnaptysBio has been able to use its technology to develop 2 compelling lead drug candidates. Their pipeline has 2 key readouts in December 2024 and February 2025 worth monitoring. The near-term catalysts include a Phase 2b trial for the drug candidates rosnilimab and ANB032, which are crucial for re-evaluating AnaptysBio’s stock value. Despite this promising pipeline and experienced leadership team, the competitive landscape within immunology and potential clinical trial failures present substantial risks to AnaptysBio’s progress. Read the full article on Seeking Alpha
Artículo de análisis • Nov 07

AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

The AnaptysBio, Inc. ( NASDAQ:ANAB ) share price has fared very poorly over the last month, falling by a substantial...
Seeking Alpha • Nov 01

AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs

Summary ANAB has a past history of successes. There are two molecules in phase 2, but with no patient data. The GSK news has hurt the stock. Read the full article on Seeking Alpha
Seeking Alpha • Aug 15

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Summary AnaptysBio, Inc. 14-week results from the phase 2b study, using ANB032 for the treatment of patients with moderate-to-severe Atopic Dermatitis, expected in December 2024. The global Atopic dermatitis market is expected to reach $19.49 billion by 2034. Top-line 12-week data from the phase 2b study, using rosnilimab for the treatment of patients with moderate-to-severe rheumatoid arthritis, expected in Q1 of 2025. The company raised $100 million in gross proceeds through a registered direct stock offering, substantially increasing its cash runway. Read the full article on Seeking Alpha
Seeking Alpha • Jul 08

AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)

Summary AnaptysBio, Inc. receives a "Hold" rating for its U.S.-listed shares. It shows a 16.42% increase in stock market value since the last "Buy" rating. AnaptysBio's immunotherapy portfolio includes promising projects such as Rosnilimab, ANB032, ANB033, Imsidolimab, and Etokimab, with positive progress and the potential to develop into a profitable source of income. Financial partnership with GSK plc also bodes favorably with AnaptysBio's hopes for additional growth, despite a net loss in the first quarter of 2024. As in the past, the apparent continuation of Fed tightening for a longer period than market participants expect will create downward pressure. This analysis concludes that there are good reasons to believe that another sharp price drop is on the horizon. Read the full article on Seeking Alpha
Artículo de análisis • May 22

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders will have a reason to smile today, with the analysts making substantial...
Artículo de análisis • May 12

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

There's been a notable change in appetite for AnaptysBio, Inc. ( NASDAQ:ANAB ) shares in the week since its...
Artículo de análisis • Feb 22

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Artículo de análisis • Oct 10

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dan Faga en comparación con los beneficios de AnaptysBio?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2026n/an/a

-US$27m

Dec 31 2025US$6mUS$706k

-US$13m

Sep 30 2025n/an/a

-US$85m

Jun 30 2025n/an/a

-US$133m

Mar 31 2025n/an/a

-US$141m

Dec 31 2024US$14mUS$685k

-US$145m

Sep 30 2024n/an/a

-US$166m

Jun 30 2024n/an/a

-US$170m

Mar 31 2024n/an/a

-US$163m

Dec 31 2023US$7mUS$641k

-US$164m

Sep 30 2023n/an/a

-US$148m

Jun 30 2023n/an/a

-US$144m

Mar 31 2023n/an/a

-US$137m

Dec 31 2022US$25mUS$474k

-US$129m

Sep 30 2022n/an/a

-US$135m

Jun 30 2022n/an/a

-US$108m

Mar 31 2022n/an/a

-US$76m

Dec 31 2021US$310kn/a

-US$58m

Compensación vs. Mercado: La compensación total ($USD6.13M) de Dan está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.45M).

Compensación vs. Ingresos: La compensación de Dan ha sido consistente con los resultados de la empresa en el último año.

CEO

Dan Faga (45 yo)

4.2yrs
Permanencia
US$6,133,943
Compensación

Mr. Daniel R. Faga, also known as Dan, is President, chief executive officer and Director of AnaptysBio, Inc. from August 2023. He was Interim President & CEO and Director of AnaptysBio, Inc. from March 21...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Daniel Faga
President4.2yrsUS$6.13m1.71%
$ 30.0m
Christopher Murphy
Chief Financial Officerno datasin datossin datos
Beth Mueller
Senior Vice President of Human Resources6.6yrssin datossin datos
Martin Dahl
Senior Vice President of Research4.3yrssin datossin datos
Benjamin Stone
Chief Business Officer2.3yrssin datossin datos
Monique Da Silva
Senior Vice President of Corporate Affairs2.3yrssin datossin datos
Priya Raina
Senior Vice President of Clinical Operations2.3yrssin datossin datos
Cailin Sibley
Senior Vice President of Translational Medicineno datasin datossin datos
John Kwon
Vice President of GI Clinical Developmentno datasin datossin datos
2.3yrs
Permanencia media
41yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de ANAB se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Daniel Faga
President4.5yrsUS$6.13m1.71%
$ 30.0m
John Orwin
Independent Chairman of the Board2.7yrsUS$370.23k0.037%
$ 644.3k
Hollings Renton
Lead Independent Director10.9yrsUS$426.69k0.017%
$ 299.9k
John Schmid
Independent Director10.9yrsUS$336.98k0.11%
$ 1.9m
Owen Hughes
Directorno datasin datossin datos
Susannah Gray
Independent Directorless than a yearsin datossin datos
Oleg Nodelman
Independent Director5.1yrssin datossin datos
Dolca Thomas
Member of Scientific Advisory Board3.3yrssin datossin datos
Luisa Salter-Cid
Member of Scientific Advisory Boardno datasin datossin datos
Christopher Hunter
Member of Scientific Advisory Boardno datasin datossin datos
John Monroe
Member of Scientific Advisory Boardno datasin datossin datos
3.9yrs
Permanencia media
60yo
Promedio de edad

Junta con experiencia: La junta directiva de ANAB se considera experimentada (3.9 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/22 22:50
Precio de las acciones al final del día2026/05/22 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

AnaptysBio, Inc. está cubierta por 19 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Neena Bitritto-GargBaird
Etzer DaroutBarclays
Michael KingCitizens JMP Securities, LLC